X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NST-6179 (orziloben) is a novel, orally administered, highly potent, synthetic, medium chain fatty acid analogue. It is being evaluated for the treatment of intestinal failure-associated liver disease.
Lead Product(s): Orziloben
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-6179
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
SEFA-6179 is a novel, oral, fully synthetic medium chain fatty acid analog for the treatment of Intestinal Failure-Associated Liver Disease and received FDA Rare Pediatric Disease Designation.
Lead Product(s): SEFA-6179
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SEFA-6179
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
NST-4016 (icosabutate), is a once-daily, oral SEFA currently in Phase 2b clinical trial for non-alcoholic steatohepatitis. It has demonstrated dose-dependent and significant improvements in all liver function parameters as well as in inflammatory and fibrotic biomarkers.
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-4016
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated liver disease (IFALD).
Lead Product(s): SEFA-6179
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SEFA-6179
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2022
Details:
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile.
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: NST-4016
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
SEFA-1024 is a novel chemically modified fatty acid derived from naturally occurring fatty acid EPA. Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with high plasma triglyceride levels.
Lead Product(s): SEFA-1024
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SEFA-1024
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Proceeds will be used to progress the SEFA development pipeline: Completion of Ph 2b study of lead programme Icosabutate in (NASH) Initiation of clinical development of two new programmes for (PNALD)
Lead Product(s): Icosabutate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
